Metraipolis › archive › dc_cc8b702eb386

Case Report: Lorlatinib combined with chemotherapy and anti-angiogenic therapy shows promising efficacy in an ALK gene fusion lung adenocarcinoma patient with… — Europe PMC PMID:42682602

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/42682602
DOI
10.3389/fphar.2026.1876652
License (as archived)
solo-consultazione
Archived
2026-10-08T09:14:25.034Z
SHA-256 of the archived text
9ae885578231780536957b01684b2faab2e78c3140fc32e4886708296f2b61f6
Stable URL of this page
https://metraipolis.com/documento/dc_cc8b702eb386

How to cite

Case Report: Lorlatinib combined with chemotherapy and anti-angiogenic therapy shows promising efficacy in an ALK gene fusion lung adenocarcinoma patient with… — Europe PMC PMID:42682602 — Europe PMC (en), https://europepmc.org/article/MED/42682602 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_cc8b702eb386 (Metraipolis archive dc_cc8b702eb386, sha256 9ae885578231780536957b01684b2faab2e78c3140fc32e4886708296f2b61f6)
BibTeX
@misc{dccc8b702eb386,
  title = {Case Report: Lorlatinib combined with chemotherapy and anti-angiogenic therapy shows promising efficacy in an ALK gene fusion lung adenocarcinoma patient with… — Europe PMC PMID:42682602},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/42682602},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_cc8b702eb386; sha256 9ae885578231780536957b01684b2faab2e78c3140fc32e4886708296f2b61f6},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/42682602. Agents can read the archived copy with the MCP tool read_document.